RNS Number : 3585V
Genedrive PLC
14 August 2025

**genedrive plc**
**("genedrive" or the "Company")**

**Comment re: Share Price Movement**

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, notes the fall in the Company's share price on 13 August 2025 which it believes was connected to postings on the London South East Chat GDR Chat (https://www.lse.co.uk/ShareChat.html?ShareTicker=GDR) noting apparent communications from a member of staff at NICE with a member of the public.

The Company wishes to highlight that the apparent communication refers to services provided by NHS Genomic Services overseeing laboratory genomic testing and not point of care technologies. The funding position is being kept under active review as noted in the apparent communication.

Furthermore, whilst the Company is aware of the completion of the NHSE CYP2C19 pilot assessing logistics of deploying as a service at scale via laboratory or point of care, and what, based on interim assessment it anticipates to be a positive outcome supporting the role and impact of rapid CYP2C19 genetic testing in stroke patients, it has not yet been made aware of a publication date by NHSE and cannot confirm the dates reportedly conveyed in the communication.

Details of the interim assessment can be found:
https://www.nw-gmsa.nhs.uk/about-us/our-projects/genomic-networks-excellence/pharmacogenomics-and-medicines-optimisation-genomic-network-excellence/clopidogrel-pilot-project-cyp2c19-genetic-testing-stroke-and-tia-patients

For further details please contact:

| | |
|---|---|
| **genedrive plc**<br>Gino Miele: CEO / Russ Shaw: CFO | +44 (0)161 989 0245 |
| **Peel Hunt LLP (Nominated Adviser and Broker)**<br>James Steel | +44 (0)20 7418 8900 |
| **Walbrook PR Ltd (Media & Investor Relations)**<br>Anna Dunphy | +44 (0)20 7933 8780 or genedrive@walbrookpr.com<br>+44 (0)7876 741 001 |

**About genedrive plc (http://www.genedriveplc.com)**

genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care

healthcare paradigms. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners and deployed on its point of care thermocycler platform. Both tests are single-use disposable cartridges which are ambient temperature stable, circumventing the requirement for cold chain logistics. The Directors believe the Genedrive® MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway. Its CYP2C19 ID Kit which has no comparably positioned competitor currently allows clinicians to make a decision on the use of Clopidogrel in stroke patients in 70 minutes, ensuring that patients who are unlikely to benefit from or suffer adverse effects from Clopidogrel receive an alternative antiplatelet therapeutic in a timely manner, ultimately improving outcomes. Both tests have undergone review by the National Institute for Health and Care Clinical Excellence ("NICE") and have been recommended for use in the UK NHS. The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCKZLBFEVLXBBZ